Streptococcus pneumoniae is the leading cause of vaccine-preventable deaths among children younger than 5 years of age worldwide. The 7-valent pneumococcal conjugate vaccine (PCV7) is currently ...
Findings presented at IDWeek 2025 underscore the importance of considering serotypes that disproportionately impact adults in the U.S. and show greater resistance to commonly prescribed antibiotics ...
Pediatric carriage rates have remained stable since 2018, and invasive pneumococcal disease incidence in young children was less than half that at the start of the vaccination program, with more than ...
Continued transboundary expansion increases the risk of introduction via international travel, contaminated animal products ...
Approved 15 months ago as a pneumococcal disease vaccine for adults—and billed as the first shot designed for seniors—Merck’s Capvaxive now has data supporting its potential in children and ...
The FDA has approved the world’s first pneumococcal disease vaccine designed for adults, signing off on Merck’s Capvaxive (formerly V116) and positioning it to become the primary shot used by seniors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results